Prof. Jane Apperley (UK) chairs an expert panel to discuss the key data and findings from the CML scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.

Prof. John Gribben (UK) chairs an expert panel to discuss the key data and findings from the MDS/AML scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.

Prof. Martin Dreyling (Germany) chairs an expert panel to discuss the key data and findings from the FL/DLBCL/MCL scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.

Dr. Jacopo Mariotti discusses his top highlights of the data and findings from the GvHD scientific sessions at the ASH 2020.

Professor António Almeida discusses his top highlights of the data and findings from the MDS/AML scientific sessions at the ASH 2020.

Professor Giovanna Russo and Professor Raffaella Colombatti discuss their top highlights of the data and findings from the Sickle cell scientific sessions at the ASH 2020.

Dr. Sabine Eichinger and Dr. Johanna Gebhart discuss their top highlights of the data and findings from the ITP scientific sessions at the ASH 2020.

Dr. Christopher Fox and Dr. Wendy Osborne discuss their top highlights of the data and findings from the FL/DLBCL scientific sessions focusing on CAR-T cell therapies at the ASH 2020.

Dr. Massimo Breccia discusses his top highlights of the data and findings from the MPN scientific sessions at the ASH 2020.

Dr. Massimo Breccia discusses his top highlights of the data and findings from the CML scientific sessions at the ASH 2020.

Chinese researchers have identified predictive and prognostic factors for intracranial hemorrhage in immune thrombocytopenia patients older than 60 years of age.

Extended follow-up of a phase 1b trial shows that responses to sutimlimab are maintained after more than a year of treatment in a subset of chronic immune thrombocytopenia patients with an inadequate response to multiple previous therapies.

Gian Luca Forni shares data on the prevalence and outcomes of SARS-CoV-2 infection in Italian patients with thalassemia or sickle cell disease.

A chemotherapy-free allogeneic hematopoietic transplantation regimen is feasible and could reduce the risk of graft-versus-host disease and relapse in patients with acute myeloid leukemia… (read more)

Identifying certain subpopulations of T and natural killer cells could help to diagnose pediatric chronic GvHD at the onset of the disorder… (read more)

Rick Kapur offers insights on the findings of a literature review looking at variability in platelet count and bleeding outcomes in patients with immune thrombocytopenia and the need for standardization.

Early results for the oral Bruton tyrosine kinase (BTK) inhibitor rilzabrutinib support its use in patients with relapsed or refractory immune thrombocytopenia (ITP). David Kuter, from Massachusetts... (read more)

Delphine Rea presents the International Chronic Myeloid Leukemia Foundation’s CANDID study findings showing that age is the most significant risk factor for COVID-19 mortality in CML patients.

Findings from a proof-of-principle study indicate that use of the JAK1 inhibitor itacitinib alongside a calcineurin inhibitor may help prevent GvHD after transplantation… (read more)

Naranie Shanmuganathan describes the characterization of cancer-related mutations at time of first-line treatment initiation for chronic myeloid leukemia and their relationship to patient prognosis.

Mohamad Mohty highlights the findings from the ROCKstar study showing a good response to belumosudil among heavily pretreated patients with chronic graft-versus-host disease.

Selim Corbacioglu discusses the CLIMB SCD-121 and CLIMB THAL-111 trials demonstrating the potential of CTX001, a novel CRISPR-Cas9 gene editing therapy, for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia, respectively.

Shehu Umar Abdullahi takes us through the SPRINT study establishing fixed low-dose hydroxyurea with biannual complete blood counts as an appropriate strategy in low-income settings for preventing secondary strokes in children with sickle cell disease.

Maria Lozano comments on the trial showing the benefits of combining mycophenolate with corticosteroid in the first-line setting and outlines what this might mean for early intensive therapy in immune thrombocytopenia.